

2024 SCIENCE2 STARTUP

Wednesday, April 10
Cambridge, MA

SPONSORED BY



Deloitte.



PRESENTED BY



F-PRIME



RACAPITAL

MENTORSHIP
POWERED BY
MASSBIO





WELCOME



LOCATION

Broad Institute of MIT and
Harvard, Cambridge, MA

DATE

Wednesday, April 10, 2024

WEBSITE

www.science2startup.com

SOCIAL MEDIA

Follow hashtag
#Science2Startup on
LinkedIn and Twitter for
event updates!

WELCOME TO SCIENCE2STARTUP

S2S is a forum for top scientists from around the world to present their ideas and interact with leading investors and executives in the Boston biotechnology hub.

Since 2008, investigators from institutions including Brown, Carnegie Mellon, Columbia, Harvard, Johns Hopkins, MIT, Northwestern, NYU, Purdue, Scripps, UCLA, University of Iceland, University of Ottawa, University of Pennsylvania, University of Pittsburgh, Yale, and many more, have presented their startup ideas at S2S and its precursor, the University Research and Entrepreneurship Symposium (URES).

We hope you enjoy the 2024 program and take full advantage of the opportunity to connect with all the pioneers in the field that have assembled for this year's event.

UNIVERSITY PARTICIPANTS



Northwestern
University



HARVARD
UNIVERSITY



UC San Diego



ACADEMIC WORKSHOPS

- 7:30 AM | Registration & Breakfast
- 8:00 AM | Opening Remarks
- 8:05 AM | Workshops
Goodwin | Colliers | Silicon Valley Bank |
Deloitte | Evotec
Workshop presentations are 25 minutes each
- 10:10 AM | Break & Networking

S2S™ AGENDA

APRIL 10TH, 2024

● 10:10 AM | Symposium Registration

● 10:35 AM | Welcome & Fireside Chat Introduction

● 10:40 AM | Fireside Chat: Translating Academic Science

Presented by: David Liu, Ph.D.

Moderated by: Deb Palestrant, Ph.D.

● 11:10 AM | Presentations: Part I

Spt5-Pol II Inhibitors as an Effective Therapeutic Approach for Huntington's Disease

Presented by: Rivka Dikstein, Ph.D.

Targeting Opportunistic Kinases for Treatment of Endometriosis

Presented by: Martin Matzuk, M.D., Ph.D.

Lysine Therapeutics

Presented by: Sander Houten, Ph.D.

Phosphatase-Targeted Biologics for Autoimmunity

Presented by: Stephanie Stanford, Ph.D.

● 12:30 PM | Lunch & Networking

● 1:30 PM | Panel Discussion: Establishing DC Criteria

Presented by: Fraser McIntosh | Alison Tisdale, Ph.D. | Barry Touré, Ph.D. | Ramin Farzaneh-Far, M.D.

Moderated by: Chong Xu, Ph.D.

● 2:00 PM | Presentations: Part II

Development of a Therapeutic with the Benefits of Estrogen but without the Risk for Breast Cancer

Presented by: William Donaldson, Ph.D.

Cyclimid Therapeutics

Presented by: Christina Woo, Ph.D.

Restoring Natural Ovarian Endocrine Function for Pediatric Cancer Survivors

Presented by: Ariella Shikanov, Ph.D.

Broadening Glioblastoma Responses with Tri-Specific T cell Engaging Antibody

Presented by: Irina Balyasnikova, Ph.D.

● 3:30 PM | Closing Remarks

● 4:00 PM | Cocktails & Networking

Cocktails and networking will adjourn at 6:00 PM



FINALISTS



Rivka Dikstein, Ph.D.

Professor & Dean of Biochemistry
Weizmann Institute of Science


Spt5-Pol II Inhibitors as an Effective Therapeutic Approach for Huntington's Disease



Irina Balyasnikova, Ph.D.

Professor of Neurological Surgery
Northwestern University

Broadening Glioblastoma Responses with Tri-Specific T cell Engaging Antibody



William Donaldson, Ph.D.

CEO
Estrigenix Therapeutics

Development of a Therapeutic with the Benefits of Estrogen but without the Risk for Breast Cancer



Sander Houten, Ph.D.

Associate Professor
Icahn School of Medicine at Mount Sinai

Lysine Therapeutics



Martin Matzuk, M.D., Ph.D.

Director, Center for Drug Discovery & Chair, Department of Pathology & Immunology
Baylor College of Medicine

Targeting Opportunistic Kinases for Treatment of Endometriosis



Ariella Shikanov, Ph.D.

Associate Professor of Biomedical Engineering
University of Michigan


Restoring Natural Ovarian Endocrine Function for Pediatric Cancer Survivors



Stephanie Stanford, Ph.D.

Director
Knobis Bio, Inc.

Phosphatase-Targeted Biologics for Autoimmunity



Christina Woo, Ph.D.

Morris Kahn Associate Professor of Chemistry & Chemical Biology
Harvard University

Cyclimid Therapeutics

SPEAKERS & PANELISTS

FIRESIDE CHAT

David Liu, Ph.D. is the Richard Merkin Professor, Director of the Merkin Institute of Transformative Technologies in Healthcare, and Vice-Chair of the Faculty at the Broad Institute of MIT and Harvard; Thomas Dudley Cabot Professor of the Natural Sciences & Professor of Chemistry and Chemical Biology at Harvard University; and Howard Hughes Medical Institute Investigator.

His major research interests include the engineering, evolution, and in vivo delivery of genome editing agents to study and treat genetic diseases; the evolution of novel therapeutic proteins using phage-assisted continuous evolution (PACE); and the discovery of bioactive synthetic molecules using DNA-templated organic synthesis and DNA-encoded libraries.

As a renowned business leader, he has successfully launched, led and scaled companies and products in the healthcare space.

DAVID LIU, PH.D.



SPEAKER:
FIRESIDE CHAT

DEB PALESTRANT, PH.D.



MODERATOR:
FIRESIDE CHAT

Deborah Palearant, Ph.D., M.B.A joined 5AM Ventures in 2018 and is a Partner and Executive Chair of 4:59 Initiative. She has over 20 years of life sciences industry experience including drug discovery, company creation, operations, business development, and strategy.

Dr. Palearant serves on the Board of Directors of Latigo Biotherapeutics and Nido Biosciences. She also serves on the Board of Directors and as Treasurer of the New England Venture Capital Association and is a member of the Boston Board of Managers at Life Science Cares. In 2010, she joined Third Rock Ventures as a Senior Associate and helped to build and launch Blueprint Medicines and Editas Medicine.

Dr. Palearant holds a Ph.D. in Biochemistry and Molecular Biophysics from Columbia University, an M.B.A from Northeastern University, and was Damon Runyon Cancer Research Foundation Postdoctoral Fellow at The Scripps Research Institute.

SPEAKERS & PANELISTS

PANEL DISCUSSION: ESTABLISHING DC CRITERIA

CHONG XU, PH.D.



**MODERATOR:
PANEL**

Chong is a Partner at F-Prime Capital. He focuses primarily on biopharmaceutical and medical technology sectors and works closely with the Eight Roads Ventures Asia team to manage portfolio companies and new investment opportunities in China.

At F-Prime, Chong has been involved in a number of company formations including as a founding investor of Skyline Therapeutics, K36 Therapeutics, and RareStone Group. Prior to joining F-Prime in 2015, Chong was an associate in McKinsey and Company's Boston office, a hedge fund healthcare equity analyst with Massif Partners and Affirmed Healthcare, and a researcher focusing on developmental neurobiology at Temasek Life Sciences Laboratory in Singapore.

Chong holds a Ph.D. in Cell Biology from University of Virginia and a M.B.A. from Darden School of Business, University of Virginia. He received his B.S. in biology from Zhejiang University, China.

SPEAKERS & PANELISTS

ALISON TISDALE, PH.D.

Alison Tisdale is an Entrepreneur In Residence (EIR) at RA Ventures, focusing on the discovery and development of novel biologics. Before joining RA, Alison was most recently Vice President of Therapeutic Discovery at Seeker Biologics, where she led the development of a high-throughput functional screening platform for multi-specific biologics, and oversaw discovery efforts for the company's pipeline of antibodies targeting pathologic cell types in autoimmune diseases.

Prior to that, Alison was a founding employee at Immunitas Therapeutics, a clinical stage biotech, where she built their discovery and engineering platform and helped shepherd the company's lead immuno-oncology program into the clinic. Alison has also held roles leading programs and teams at other biotech startups including Generate Biomedicines and Eleven Biotherapeutics.

She has a BS and MS in Chemical Engineering, and earned her PhD in Biological Engineering from MIT.



PANELIST:
ESTABLISHING DC CRITERIA

BARRY TOURÉ, PH.D.



PANELIST:
ESTABLISHING DC CRITERIA

Barry Touré brings 18 years of drug discovery, team building and leadership experience in startups.

Most recently, he was the first employee and Head of Drug Discovery at Nido Biosciences, a clinical stage neuroscience biotech, where he built and led multiple functions and played a pivotal role in the discovery and early development of NIDO-361. Previously, he was a founding team member at Relay Therapeutics (NASDAQ: RLAY, clinical stage biotech) and played an instrumental role in building the chemistry function, leading projects, and integrating the platform technologies in medicinal chemistry. Prior to Relay, Barry spent 10 years in the Global Discovery Chemistry organization at Novartis supporting and leading several oncology and neuroscience projects. He has contributed to the discovery of multiple clinical candidates including RLY-4008 (Lirafugratinib, Phase 2), NIDO-361 (Phase 2), TNO155 (Batoprotafib, Phase 1b/2), and has authored 50+ patents and peer-reviewed articles.

Barry was an NSERC Canada postdoctoral fellow at Columbia University. He holds a B.Sc. and M.Sc. respectively in Chemistry and Biomedical Sciences from the University of Montreal and was a CHIR doctoral fellow at the University of Alberta, where he earned a Ph.D. in Chemistry.

SPEAKERS & PANELISTS

RAMIN FARZANEH-FAR, M.D.

Ramin Farzaneh-Far, M.D., is Capstan's Chief Medical Officer.

Prior to Capstan, he was at RA Capital where he was a Venture Partner. Previously, he was Chief Medical Officer at Ra Pharmaceuticals from 2016 until its acquisition by UCB in 2020 and led the clinical development of zilucoplan (Zilbrysq®), a complement C5 inhibitor recently approved in the United States, Europe, and Japan for the treatment of generalized myasthenia gravis. He previously led global clinical development programs at Akebia Therapeutics and Gilead Sciences.

Dr. Farzaneh-Far completed his internal medicine residency at Brigham and Women's Hospital in Boston and a fellowship in cardiovascular medicine at the University of California, San Francisco (UCSF). He holds B.A. and M.A. degrees in immunology from the University of Cambridge, an M.D. from University College London, and an MAS in clinical research from UCSF.



PANELIST:
ESTABLISHING DC CRITERIA

FRASER MCINTOSH



PANELIST:
ESTABLISHING DC CRITERIA

Fraser is a pharmacologist by training and has more than 30 years in the drug discovery industry.

He is currently employed at Evotec where he is head of global in-vivo pharmacology and supports several integrated strategic partnerships with biopharmaceutical companies.

Prior to Evotec, Fraser lead operational and projects teams at Pfizer and AstraZeneca in the UK and Canada where he was involved in >15 preclinical candidate nominations spanning multiple therapeutic areas including autoimmune disease, CNS/Pain, respiratory and fibrosis.

ADVISORY GROUP



Anurag Agarwal, Ph.D.

Partner
OUP



Jessica Alston, Ph.D.

Partner
F-Prime Capital



Kevin Bitterman, Ph.D.

Partner
Atlas Venture




Laura Brass, Ph.D., M.B.A.

Managing Director
Novartis Venture Fund



Christine Brennan, Ph.D.

Managing Director
Vertex Ventures HC



Uya Chuluunbaatar, Ph.D.

Partner
Avoro Ventures



Matt Cohen, Ph.D.

Managing Partner
OUP



Shinichiro Fuse, Ph.D.

Partner &
Managing Director
TPG Life Sciences Innovation



Evan Gallagher

Executive Vice President
Colliers



Christina Isacson, Ph.D.

Partner
Lightstone Ventures




Sacha Mann, M.B.A.

Senior Investment Director & Partner
Takeda Ventures



Annie Mitsak, Ph.D.

Partner
Cure Ventures



Deb Palestrant, Ph.D.

Partner &
Executive Chair
4:59 Initiative,
5AM Ventures



Jason Ruth, Ph.D.

Partner
MRL Ventures



Joshua Resnick, M.D.

Managing Director
RA Capital



Christian Schubert, Ph.D.

Vice President & Head
AbbVie Ventures



Jeff Stevens, M.B.A.

Head
Alexandria LaunchLabs



Anna Turetsky, Ph.D.

Principal of Venture Investments
The Mark Foundation



Stacie Weninger, Ph.D.

President
FBRI



ACADEMIC WORKSHOPS

BUSINESS PLAN MUST GUIDE THE REAL ESTATE, NOT THE OTHER WAY AROUND



Evan Gallagher

Executive Vice President



Evan Gallagher is a veteran life science real estate advisor specializing in tenant representation in all the Greater Boston lab clusters. His in-depth market knowledge of lab and GMP space, relationships throughout the life science industry and deep experience representing biotech companies in the area sets him apart from other real estate advisors in the market.

Evan is widely known for being a frontrunner in the life science real estate industry in the Boston area. An extremely strong advocate and negotiator on behalf of his clients, Evan built the Life Science Practice Team at Colliers' Boston office and is well-versed in all aspects of design and construction of laboratory and GMP manufacturing facilities.

Evan has worked in the commercial real estate industry for 20 years, focusing solely on the life science sector for the past 15 years, and representing 200+ life science companies throughout his 20-year career.



Caitlin Mahoney

Life Sciences Advisor



Caitlin joined Colliers in 2021, serving as an Advisor on the Boston Life Science Practice Team. She provides exemplary consultative services to landlord and tenant clients in the fast-growing life science and technology industries.

Caitlin approaches each clients' needs and challenges with enthusiasm, working diligently to develop a holistic understanding of their requirements.

As a member of the Boston Life Science Practice Team, Caitlin supports a wide range of tenants, from Discovery through Commercial functions.

ACADEMIC WORKSHOPS

CONSIDERATIONS FOR SETTING UP YOUR FINANCE ORGANIZATION DURING COMPANY SCALING



B.J. Spence

Partner, Accounting & Reporting Advisory (ARA)
New England Leader



B.J. currently leads Deloitte's Accounting & Reporting Advisory (ARA) practice in New England. In this role, B.J. is responsible for overseeing the execution and delivery of services that are targeted at helping those in the Accounting/Finance Department solve their most complex and challenging projects.

B.J. has extensive experience over 16+ years of working with a wide array of public and private companies of all sizes and across all industries, with a particular focus on companies in the life sciences and biotech industries, including early stage and growing organization.

B.J. and his team are also focused on working closely with individuals in the accounting and finance departments, which includes supporting them as they prepare to enhance their financial statements, business processes, controls, and overall organization as they adapt to challenges commonly faced when navigating U.S. GAAP, SEC, regulatory, and auditor requirements.

READE INITIATIVE



Fraser McIntosh

EVP, Head of Global
In-Vivo Pharmacology



Fraser is a pharmacologist by training and has more than 30 years in the drug discovery industry.

He is currently employed at Evotec where he is head of global in-vivo pharmacology and supports several integrated strategic partnerships with biopharmaceutical companies.

Prior to Evotec, Fraser lead operational and projects teams at Pfizer and AstraZeneca in the UK and Canada where he was involved in >15 preclinical candidate nominations spanning multiple therapeutic areas including autoimmune disease, CNS/Pain, respiratory and fibrosis.

ACADEMIC WORKSHOPS

BANKING INNOVATION: CONSIDERATIONS FOR EARLY-STAGE LIFE SCIENCE COMPANIES



Nate Meaux

Director,
Head of Northeast Bio,
Relationship Management



Nate has spent the last decade underwriting and executing venture debt facilities to the life sciences and healthcare ecosystem; committing >\$1Bn in debt capital to companies during that time.

In his current role, Nate's team supports post-Series A life sciences companies with all of their banking and capital needs by leveraging deep knowledge of the unique challenges drug developers face in order to help patients.



Mike Ritter

Vice President,
Early Stage Biopharma,
Relationship Management



As Vice President in SVB's Northeast Life Science Startup Banking Practice, Mike brings his passion for early-stage development to founders with a focus on biopharma, diagnostics, medical devices, and health-tech.

Mike supports clients in all things banking and beyond, including potential introductions to investors and the various ecosystem partners who help clients thrive from day one.

SIX MISTAKES FOUNDERS MAKE



Bill Collins

Life Sciences Partner



Bill Collins is a partner in Goodwin's globally recognized Life Sciences group, counseling clients in the industries of biotechnology, pharmaceuticals, and medical devices. Serving as his clients' principal outside counsel, Bill provides strategic advice and corporate legal counseling to management teams and boards while structuring and leading significant transactions on his clients' behalf through their full corporate life cycle.

Bill has extensive experience with startup and formation matters, venture capital financings, initial public offerings, deSPAC transactions, and other equity debt capital markets transactions, mergers and acquisitions, strategic collaborations, and other complex transactions.

He also represents several publicly traded biotechnology companies in ongoing SEC compliance, capital raising, and corporate governance matters, and spends much of his time advising founders, executives, and directors on business and legal matters alike.

SPONSORED BY

DIAMOND SPONSORS



Colliers is a leading diversified professional services and investment management company. With operations in 66 countries, our 19,000 enterprising professionals work collaboratively to provide expert real estate and investment advice to clients. For more than 28 years, our experienced leadership with significant inside ownership has delivered compound annual investment returns of approximately 20% for shareholders. With annual revenues of \$4.5 billion and \$98 billion of assets under management, Colliers maximizes the potential of property and real assets to accelerate the success of our clients, our investors and our people. Learn more at corporate.colliers.com, X @Colliers or LinkedIn.



Deloitte provides industry-leading audit, consulting, tax and advisory services to many of the world's most admired brands, including more than 85 percent of the Fortune 500 and more than 6,000 private and middle market companies. Our people work across more than 20 industry sectors to make an impact that matters —delivering measurable and lasting results that help reinforce public trust in our capital markets, inspire clients to see challenges as opportunities to transform and thrive, and help lead the way toward a stronger economy and a healthy society. Deloitte is proud to be part of the largest global professional services network serving our clients in the markets that are most important to them.



Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academic groups, patient advocacy groups and venture capitalists. Drug discovery solutions are provided in form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of innovative drug candidates and consulting arrangements. With over 2,500 employees worldwide and leading scientific experts, state-of-the-art technologies as well as key therapeutic expertise in the areas of neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis, Evotec intends to develop best-in-class and first-in-class differentiated therapeutics on its systematic, unbiased and comprehensive infrastructure through long-term discovery alliances, investments and academic BRIDGE partnerships.

SPONSORED BY

PLATINUM SPONSOR



Goodwin partners with clients to practice law with integrity, ingenuity, agility and ambition. With 1,000-plus lawyers across the United States, Europe and Asia, the firm excels at complex transactions, high-stakes litigation and world-class advisory services in the technology, life sciences, real estate, private equity, and financial industries. The firm is set apart by a unique combination of deep experience serving both the innovators and investors in a rapidly-changing, technology-driven economy. Information may be found at www.goodwinlaw.com. Follow us on Twitter @goodwinlaw.

GOLD SPONSORS



Pliancy specializes in providing end-to-end IT solutions and ongoing support for today's highest-executing Capital Management and Life Sciences organizations to help secure and scale their technology. Using a personal, process-driven approach with white-glove service, we liberate our customers to do their best work by streamlining and automating processes while protecting their data. We innovate towards simplicity and sustainability through cloud-native strategies, future-proofing our clients' processes in a constantly evolving tech landscape. Learn more at www.pliancy.com.



As the largest banking team with a 40-year history dedicated to the innovation economy, Silicon Valley Bank remains uniquely positioned to deliver specialized financial services with unmatched expertise. With the strength and stability of First Citizens Bank behind us, we're here and committed to helping life science and healthcare founders become true game changers. Silicon Valley Bank (svb.com).

STEERING COMMITTEE



Raj Basak, Ph.D.
Associate
F-Prime Capital




Patrice Groomes Ghosh, Ph.D.
Analyst
Atlas Venture



Davina Magargal
VP of Marketing
F-Prime Capital



Mitra Miri, Ph.D.
Principal
OUP



Kevin Corsini Rosewood
Office Manager &
Administrative Assistant
5AM Ventures



Katie Bodner Spielberg, Ph.D.
Senior Associate
5AM Ventures



Katharine Unangst
Executive Assistant
Atlas Venture



Britt Inga Emerson
Investor Relations
Manager
5AM Ventures




Jenna Hebert, Ph.D.
Senior Associate
RA Capital
Management



Kayti Mangels
Executive Assistant
OUP



Alexander Munoz, M.D.
Associate
F-Prime Capital



Jessica Sagers, Ph.D.
Head of Engagement
RA Capital
Management



Aniq Tasnim, Ph.D.
Associate
5AM Ventures



Maurizio Fazio, Ph.D., M.D.
Principal
Atlas Venture



Allison Gosman Kanter
Marketing Manager
F-Prime Capital



Kristen Margeson
VP of Investor
Relations & Marketing
Atlas Venture



Caroline Pepek
Senior Director
of Innovation
MassBio



Rebecca Silberman, Ph.D.
Investment Director
RA Capital
Management



Emily Tynan
Marketing & Event
Coordination Manager
F-Prime Capital



Harry Won, Ph.D.
Associate
OUP



 ATLAS VENTURE

Atlas Venture is a leading biotech venture capital firm. With the goal of doing well by doing good, we have been building breakthrough biotech startups for over 25 years. We work side by side with exceptional scientists and entrepreneurs to translate high impact science into medicines for patients. Our seed-led venture creation strategy rigorously selects and focuses investment on the most compelling opportunities to build scalable businesses and realize value. For more information, please visit www.atlasventure.com.



Osage University Partners (OUP) is a venture capital firm focused on investing in startups that are commercializing pioneering university technologies. OUP partners with top research universities to invest in their most innovative startups, and OUP shares its investment profit with its partner institutions. The firm invests in software, hardware, climate tech, and life science companies at all stages of company development. Since 2009, OUP has partnered with over 100 universities, including 27 of the top 30 U.S. institutions by research expenditures, and has invested in over 130 of their spinouts. For more information, visit oup.vc.

F-PRIME

F-Prime Capital is a global venture capital firm investing in healthcare and technology. For the past 50 years, our venture capital group has had the privilege of backing great entrepreneurs building ground-breaking companies. With over \$4.5B under management and a global portfolio of more than 300 companies, we champion those dedicated to creating positive change in the world. Our team of investors, engineers, doctors, and scientists are committed to bringing the insight, domain expertise, and relationships required to help our companies make a transformational impact. For more information, please visit www.fprimecapital.com.



Founded in 2002, 5AM Ventures is a leading venture capital firm focused on building next-generation life science companies. Based in San Francisco and Boston, 5AM takes a hands-on approach to investing and company building, often going beyond traditional board roles to leverage our diverse team of scientists, clinicians, drug developers and executives throughout a company's life. With over \$2.2 billion raised since inception, 5AM has invested globally in over 100 public and private companies. For more information, please visit www.5amventures.com.

RACAPITAL

RA Capital Management is a multi-stage investment manager dedicated to evidence-based investing in public and private healthcare and life science companies that are developing drugs, medical devices, and diagnostics. The flexibility of its strategy allows RA Capital to provide seed funding to startups and to lead private, IPO, and follow-on financings for its portfolio companies, both facilitating the crossover process and allowing management teams to drive value creation with fewer capital concerns from inception through commercialization. For more information, please visit www.racap.com.

SPECIAL THANKS TO



RICK LUNDBERG
President & CEO
Eikonizo Therapeutics



JAMES ELLIS, PH.D.
CSO
Nocion Therapeutics



MEG YAO, PH.D.
Consultant
Biotech & Pharmaceutical Industries



AFSANEH MOHEBBI, PH.D.
Founder
Damavand Consulting



LISA HUANG, PH.D.
SVP, CSO Partner Team
Curie.Bio



CATHERINE MESNER
Bio-Pharma Advisor
FoleyFields



FEI SHEN, PH.D.
Managing Director
Boehringer Ingelheim Venture Fund USA



ALISON SCHECTER, M.D.
CEO
Molecules to Medicine Advisory Group